论文部分内容阅读
目的:探讨急性心力衰竭应用新活素与硝普钠治疗的临床疗效以及安全性。方法:选取2012年7月到2013年7月于我院心内科收治的68例急性心力衰竭患者作为本次研究对象,将患者随机分为研究组和对照组两组,每组各有患者34例。对照组患者采用硝普钠药物治疗,研究组患者采用新活素药物治疗,对比两组患者临床疗效与不良反应发生情况。结果:研究组患者的临床效果要明显优于对照组,存在显著性差异(P<0.05),有统计学意义;研究组患者不良反应发生率为5.88%,对照组患者不良反应发生率为11.76%,两组患者的不良反应发生情况不具明显差异(X2=0.731,P=0.393)。结论:采用新活素与硝普钠治疗急性心力衰竭均能改善患者治疗效果,但新活素的疗效更为显著,安全性更佳,可以优先选择,值得在临床上大力推广。“,”Objective: To investigate the clinical efficacy and safety of Lyophilized Recombinant Human Brain Natriuretic Peptide and Sodium Nitroprusside treatment in the acute heart failure patients. Methods: 68 cases of acute heart failure patients were recruited in our hospital from July 2012 to July 2013. The patients were randomly divided into two groups :Research group of 34 patients treated with Recombinant Human Brain Natriuretic Peptide and Control group of 34 patients treated with Sodium Nitroprusside. The clinical efficacy and adverse reactions occur ratio in both groups were compared. Results: The clinical efficacy in Research group was significantly superior to those in control group (P < 0.05). The incidence of adverse reactions in research group was lower than those in Group patients( 5.88% vs 11.76%),but no significantly difference (X2 = 0.731, P = 0.731). Conclusion: The treatment with Recombinant Human Brain Natriuretic Peptide can improve the treatment effect in acute heart failure patients ,and more security.